• CD Moderators: someguyontheinternet
  • Cannabis Discussion Welcome Guest
    Posting Rules Bluelight Rules

Pharm actions in Cannabis [image]

Shaman_RN

Bluelighter
Joined
Nov 29, 2009
Messages
270
Location
Netherlands
I found this somewhere, sometime in the past. Maybe this could go into the wiki or something?

25z56ra.jpg
 
Found it.

In case anyone cares it's in the journal "Trends in Pharmacological Sciences" volume 30 issue 1 (2009). The article is called "Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb." by Izzo, Borrelli, Capasso, Di Marzo and Mechoulam.
 
The full PDF report is here:
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
http://www.quickfilepost.com/download.do?get=86f1028e6f7f95e35d2143a87a855b69

"...Conclusions
Recent developments suggest that non-psychotropic phytocannabinoids exert a wide range of pharmacological effects (Figure 1), many of which are of potential therapeutic interest. The most studied among these compounds is CBD, the pharmacological effects of which might be explained, at least in part, by a combination of mechanisms of action (Table 1, Figure 1). CBD has an extremely safe profile in humans, and it has been clinically evaluated (albeit in a preliminary fashion) for the treatment of anxiety, psychosis, and movement disorders. There is good pre-clinical evidence to warrant clinical studies into its use for the treatment of diabetes, ischemia and cancer. The design of further clinical trials should: i) consider the bellshaped pattern of the dose–response curve that has been observed in pre-clinical pharmacology, and ii) establish if CBD is more effective or has fewer unwanted effects than other medicines. A sublingual spray that is a standardized Cannabis extract containing approximately equal quantities of CBD and D9-THC (Sativex1), has been shown to be effective in treating neuropathic pain in multiple sclerosis patients [76].

The pharmacology of D9-THCV (i.e. CB1 antagonism associated with CB2 agonist effects) is also intriguing because it has the potential of application in diseases such as chronic liver disease or obesity—when it is associated with inflammation—in which CB1 blockade together with some CB2 activation is beneficial. Concerning obesity treatment, it will be important in future studies to establish if D9-THCV is more effective or has fewer unwanted effects than rimonabant. Rimonabant was the first clinically available CB1 receptor antagonist, but was withdrawn from the market because of the increased risk of depression. The plant Cannabis is a source of several other neglected phytocannabinoids such as CBC and CBG. Although the spectrum of pharmacological effects of these compounds is largely unexplored, their potent action at TRPA1 and TRPM8 might make these compounds new and attractive tools for pain management."
 
Last edited:
sweet chart. next time someone gives me crap about weed being bad for me I'll just say 'Well actually the CBD compounds of the hash flower are a known anti-ischemic, so eat a dick' and then they will say sorry and ask to smoke with me and ask me where I got my cool homespun britches.
 
Wow I'm late on checking back to this thread 0_0

Sorry about that :\ but that's cool that the original source was found. I think I found the image in a blog some time ago.
 
Top